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Background
Not long ago, osteoporosis was considered a normal
condition specific to old age; presently, osteoporosis is
an affection characterized through the reduction of the
mineral bone density associated with the impairment of
the trabecular bone structure and implicitly with the
increase of the bone fragility. Compliance and adherence
to osteoporosis management are of high priority, having
a significant effect on the cost effectiveness of therapy 1.
Methods
The evaluation of the phosphocalcium metabolism for the
female patients with osteoporosis, before and after 1 year
since the administration of antiresorptive drugs, was rea-
lized through osteodensitometry (BMD), that was the
most conclusive paraclinical exam used in the diagnosis of
osteoporosis, the evaluation of the clinical factors and the
analysis of the bone turnover through the determination
of the biochemical turn-over markers (BTM- bone forma-
tion and resorption, pre and post-therapy). Besides the
specific analysis of these pathology was made blood
analysis.
Results
After 1 year since the administration of antiresorptive
drugs wasn’t noticed important modifications at the
BMD and biochemical markers, could contribute to the
creation of a pathogenic profile of the patient that led to
a therapeutic decision as correct as possible. BTM
changes can also be used for understanding the mechan-
ism of action of drugs in development and identifying the
correct dose 2,. Instead, at 2% of female patients could be
noticed small decreases of the serum concentrations of
calcium, as well as increases of the blood concentrations
of the total activity of the alkaline phosphatase, without
noticeable clinical consequences. Long-term alendronate
administration may inhibit normal repair of microdam-
age arising from severe suppression of bone turnover
(SSBT), which, in turn, results in accumulation of micro-
damage 3.
Conclusions
The pharmacological therapy must be extended under
periodical medical control in order to maximize the bene-
fits and to avoid side effects since, depending on the
results of the exams, it could be necessary to vary the
doses or the type of used drug. The study of the hard sup-
port tissues is rendered difficult by the fact that the bone
is one of the most unstable tissues from the organism.
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